Aim: A possible molecular mechanism of clinically defined multidrug-resistant epilepsy involves drug efflux transporters such as P glycoprotein (P-gp), a member of the ATP-binding cassette subfamily B1 (ABCB1). We have investigated the prevalence of the C3435T, G 2677T/A, and T129C single-nucleotide polymorphisms in the promoter region of MDR1 gene, in Romanian epileptic patients.
Methods: 70 epileptic patients evaluated in the Neurology Department of Cluj County Hospital were included in the study. The response to treatment was assessed by reviewing the seizure diaries and the patients were classified as responders or non-responders. Antiepileptic drug (AED) plasmatic concentrations were measured and the patients were divided into 2 groups: first group with AED concentrations in therapeutic range and the second one with sub-optimal AED concentrations. Genotyping the DNA samples, we investigated MDR1 gene polymorphism by polymerase chain reaction (PCR). Results were expressed as genotype and allele frequencies per response group and compared between subgroups.
Results: 33 patients (47.14%) were classified as responders, while the remaining 37 patients (52.86%) were classified as non-responders. A comparison of responders and non-responders revealed no significant difference in genotype frequency for any of the three mutations studied. The CT heterozygote for ABCB1 T129C had significantly lower AED concentrations (p=0.041), with no significant difference for the other polymorphisms studied.
Conclusions: In our study we found an association of CT variant in ABCB1 C129T with lower AED plasmatic concentrations and no association between ABCB1 variants and the drug responsiveness.
1. Kwan P. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1376–81. DOI: 10.1136/jnnp.2004.045690
2. Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: Multiple hypotheses, few answers. Vol. 8, Frontiers in Neurology. Frontiers Media SA; 2017. p. 301.
3. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure. 2002 Mar;11(2):77–84. DOI: 10.1053/seiz.2002.0593
4. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr 1;58(4):522–30. DOI: 10.1111/epi.13670
5. Berg A, Scheffer I. New concepts in classification of the epilepsies: Entering the 21st century - Berg - 2011 - Epilepsia - Wiley Online Library. Epilepsia. 2011.
6. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010 Mar 1;19(2):93–101. DOI: 10.1016/j.seizure.2009.12.004
7. Berg AT. Identification of Pharmacoresistant Epilepsy. Vol. 27, Neurologic Clinics. 2009. p. 1003–13. DOI: 10.1016/j.ncl.2009.06.001
8. Semah F, Picot M, Adam C, Broglin D, Arzimanoglou A, Bazin B, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology. 1998;51:1256–62. DOI: 10.1212/WNL.51.5.1256
9. Proper E a, Hoogland G, Kappen SM, Jansen GH, Rensen MG a, Schrama LH, et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain. 2002;125(Pt 1):32–43.
10. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2001;42(12):1501–6. DOI: 10.1046/j.1528-1157.2001.12301.x
11. Hartz AMS, Pekcec A, Soldner ELB, Zhong Y, Schlichtiger J, Bauer B. P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy. Mol Pharm. 2017 Apr;14(4):999–1011. DOI: 10.1021/acs.molpharmaceut.6b00770
12. Feldmann M, Asselin M-C, Liu J, Wang S, McMahon A, Anton-Rodriguez J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol. 2013 Aug;12(8):777–85. DOI: 10.1016/S1474-4422(13)70109-1
13. Mahringer A, Fricker G. ABC transporters at the blood–brain barrier. Expert Opin Drug Metab Toxicol. 2016;12(5):499–508. DOI: 10.1517/17425255.2016.1168804
14. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand. 2007;115(4):232–42. DOI: 10.1111/j.1600-0404.2006.00761.x
15. Kerb R, Aynacioglu a S, Brockmöller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 2001;1(3):204–10. DOI: 10.1038/sj.tpj.6500025
16. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009 Nov;51(6):1069–77. DOI: 10.1111/j.1528-1167.2009.02397.x
17. Volmut J, Matisová E, Ha PT. Simultaneous determination of six antiepileptic drugs by capillary gas chromatography. J Chromatogr B Biomed Sci Appl. 1990;527(C). DOI: 10.1016/S0378-4347(00)82127-1
18. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76. DOI: 10.1111/j.1528-1167.2008.01561.x
19. Buzoianu AD, Bocsan IC, Maier C, Trifa AP, Popp RA, Dumbrava LP, et al. Genotype-pheno type corelations between the aleles of the MDR1 C3435T polymorphism and pharmacokinetic parameters in Romanian epileptic patients. Ther Pharmacol Clin Toxicol. 2011;15(1):40–4.
20. Trifa AP, Popp RA, Militaru MS, Crisan TO, Farcas MF, Csernik FA, et al. The C and T alleles of the MDR1 (Multiple Drug Resistance 1) C3435T polymorphism share similar frequencies in the Romanian population. Ann RSCB. 2009;XIV(1):68–72.
21. Sabin O, Pop R, Trifa A, Buzoianu AD. The influence of CYP2C9, CYP2C19 and ABCB1 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Hum Vet Med. 2016;8(1):29–33.
22. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76(1):22–76. DOI: 10.1016/j.pneurobio.2005.04.006
23. Lai Y. Transporters in drug discovery and development : detailed concepts and best practice. Elsevier Science; 2013. 159-174 p. DOI: 10.1002/9781118354483
24. Mosyagin I, Runge U, Schroeder HW, Dazert E, Vogelgesang S, Siegmund W, et al. Association of ABCB1 genetic variants 3435C > T and 2677G > T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Prism. 2008;49(9):1555–61. DOI: 10.1111/j.1528-1167.2008.01661.x
25. Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar S V., et al. A “Silent” Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science (80-). 2007;315(5811):525–8. DOI: 10.1126/science.1135308
26. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348(15):1442–8. DOI: 10.1056/NEJMoa021986
27. Hung C-C, Tai JJ, Lin C-J, Lee M-J, Liou H-H. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 2005;6(4):411–7. DOI: 10.1517/14622418.104.22.1681
28. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure. 2006;15(1):67–72. DOI: 10.1016/j.seizure.2005.11.001
29. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia. 2005;46(5):643–7. DOI: 10.1111/j.1528-1167.2005.46304.x
30. Haerian BS, Lim KS, Mohamed EHM, Tan HJ, Tan CT, Raymond AA, et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure. 2011 Jun;20(5):387–94. DOI: 10.1016/j.seizure.2011.01.008
31. Li H, Wang B, Chang C, Wu M, Xu Y, Jiang Y. The roles of variants in human Multidrug Resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: A meta-analysis of 57 studies. PLoS One. 2015;10(3):e0122043. DOI: 10.1371/journal.pone.0122043
32. Butila AT, Sin A, Szabo ER, Micheu C, Moldovan VG, Voidazan S, et al. ABCB1 gene polymorphisms is not associated with drug-resistant epilepsy in Romanian children. Rev Rom Med Lab. 2015;23(4):469–82. DOI: 10.1515/rrlm-2015-0037
33. Shen C, Zhang B, Liu Z, Tang Y, Zhang Y, Wang S, et al. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017;51:102–6. DOI: 10.1016/j.seizure.2017.07.015
34. Lovrić M, Božina N, Hajnšek S, Kuzman MR, Sporiš D, Lalić Z, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit. 2012 Oct;34(5):518–25. DOI: 10.1097/FTD.0b013e31826517c6
35. Zhou Y, Wang X, Li H, Zhang J, Chen Z, Xie W, et al. Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015 Aug;30(4):282–7. DOI: 10.1016/j.dmpk.2015.05.002
36. Wang P, Yin T, Ma HY, Liu DQ, Sheng YH, Wang C, et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015 Nov;117:52–7. DOI: 10.1016/j.eplepsyres.2015.09.001
37. Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017 Dec;62(12):1009-14. DOI: 10.1038/jhg.2017.91